Opinion|Videos|February 27, 2024
Case 3: 70-Year-Old Former Smoker with Stage IIIB NSCLC with PD-L1 10%
Dr. Gregory Gan introduces Case 2, involving a 70-year-old former smoker with Stage IIIB NSCLC and a PD-L1 level of 10%, prompting discussion with emphasis on the importance of shared decision-making with the patient and their caregivers.
Advertisement
Episodes in this series
Advertisement
Related to this article
Dan Costin, MD, explains the rationale for testing a personalized mRNA vaccine after resection of high-risk stage I NSCLC.
Data from the REZILIENT3 trial support the NDA for zipalertinib plus chemotherapy for those with NSCLC harboring EGFR exon 20 insertion mutations.
Nitin Ohri, MD, MS, discusses how his team manages toxicity and treatment tolerance as combination regimens grow more complex.
Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer.
Nitin Ohri, MD, MS, explains the rationale for combining thoracic radiotherapy with dual PD-1 and LAG-3 blockade in locally advanced NSCLC.
Jyoti Malhotra, MD, MPH on first-in-human clinical trials, lung cancer precision medicine in 2026, the disparities tension in drug development, and her move to Yale Cancer Center.
Clinicians must think a lot about how to make testing and novel treatment advances available for patients globally, according to Chul Kim, MD, MPH.
Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small cell lung cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Expanding CAR T and Bispecific Antibody Research in HIV-Associated Lymphoma
2
Prioritizing Proton Therapy for Pelvic Nodal Irradiation in Prostate Cancer
3
Why High-Risk Stage I NSCLC Needs a Post-Surgical Vaccine Option
4
Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer
5